The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...
Nothing drives down a drug’s price like competition. According the U.S. Food and Drug Administration (FDA), a drug’s ...
While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...
Summit Therapeutics (SMMT) stock gains as Cantor Fitzgerald issues an Overweight rating highlighting the company's lead asset ...
Merck's stock recently got a cardio boost, jumping 13% in a month thanks to some pulse-quickening developments. The company ...
The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.
Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...
The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.
On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...
We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other most ...
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback